单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
英文原题:Research progress of adoptive tumor infiltrating lymphocyte therapy for cervical cancer.
Research progress of adoptive tumor infiltrating lymphocyte therapy for cervical cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
宫颈癌是全球女性癌症相关死亡的第四大原因,对女性健康构成重大威胁。免疫治疗已成为继手术、化疗和放疗之后的宫颈癌第四线治疗方法。它对复发和/或转移性宫颈癌尤其有效,可产生良好的临床结局。常见的免疫治疗方法包括免疫检查点抑制剂、过继细胞治疗和宫颈癌疫苗。其中,过继细胞免疫治疗(ACT)是一种创新且有前景的治疗方式,近年来改变了肿瘤免疫治疗领域。本综述将特别聚焦于TIL(肿瘤浸润淋巴细胞)(TILs),探讨基于TIL的宫颈癌治疗的原理、局限性、改进策略、挑战和未来前景。总体而言,这些方法为以TIL治疗为核心的宫颈癌免疫治疗提供了新的理论基础和转化研究方向。
Cervical cancer ranks as the fourth leading cause of cancer-related mortality among women globally, posing a significant threat to women's health. Immunotherapy has emerged as the fourth line of treatment for cervical cancer, following surgery, chemotherapy, and radiotherapy. It is particularly effective for recurrent and/or metastatic cervical cancer, yielding favorable clinical outcomes. Common immunotherapeutic approaches include immune checkpoint inhibitors, adoptive cell therapy, and cervical cancer vaccines.
Among these, adoptive cell immunotherapy (ACT) represents an innovative and promising modality that has transformed the field of cancer immunotherapy in recent years. This review will specifically focus on tumor-infiltrating lymphocytes (TILs), examining the principles, limitations, improvement strategies, challenges, and future prospects of TIL-based treatment for cervical cancer. Collectively, these approaches offer a novel theoretical foundation and translational research direction for cervical cancer immunotherapy centered on TIL therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。